Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. The FDA approval and launch of Anaphylm, along with international expansion plans, suggest potential growth. However, financial guidance shows a significant EBITDA loss, and there are uncertainties regarding FDA meetings and protocol modifications. The Q&A reveals positive sentiment from the allergist community and readiness for regulatory requirements, but management's vague responses on certain issues raise concerns. Overall, the combination of positive development plans and financial challenges results in a neutral sentiment.
Key Financial Performance
Total revenues (Q4 2025) $13 million, a 10% increase year-over-year from $11.9 million in Q4 2024, primarily driven by increases in manufacture and supply revenue.
Manufacturing and supply revenue (Q4 2025) $12 million, an increase from $10.7 million in Q4 2024, primarily due to increases in Suboxone and Ondif revenues.
Total revenues (Full Year 2025) $44.5 million, a 3% decrease year-over-year from $46 million (excluding onetime recognition of deferred revenues in 2024). Including deferred revenue, total revenues decreased from $57.6 million in 2024. The decrease was due to the termination of licensing and supply agreements.
Manufacturer and supply revenue (Full Year 2025) $40.2 million, a slight increase from $40 million in 2024, primarily due to increases in Ondif revenues, partially offset by decreases in Suboxone revenues.
R&D expenses (Q4 2025) $3.2 million, a decrease from $4.9 million in Q4 2024, primarily due to lower clinical trial costs for the Anaphylm development program and decreased share-based compensation.
R&D expenses (Full Year 2025) $17.2 million, a decrease from $20.3 million in 2024, primarily due to lower clinical trial costs for the Anaphylm development program, partially offset by increases in product research expenses and share-based compensation.
Selling, general and administrative expenses (Q4 2025) $32.8 million, an increase from $16 million in Q4 2024, primarily due to higher legal expenses ($13.6 million), commercial spending ($3.7 million), personnel expenses ($0.8 million), and share-based compensation ($0.2 million), partially offset by lower severance expenses ($1.7 million) and regulatory fees ($0.5 million).
Selling, general and administrative expenses (Full Year 2025) $79.8 million, an increase from $50.2 million in 2024, primarily due to higher legal fees ($14.3 million), commercial spending ($9.6 million), Anaphylm PDUFA fee ($4.3 million), personnel expenses ($1.9 million), regulatory expenses ($1 million), and share-based compensation ($0.9 million), partially offset by decreases in severance expenses ($2.8 million) and insurance expenses ($0.6 million).
Net loss (Q4 2025) $31.9 million, an increase from $17.1 million in Q4 2024, primarily driven by higher selling, general and administrative expenses, and manufacturing and supply expenses, partially offset by decreases in R&D expenses and increases in revenue and interest income.
Net loss (Full Year 2025) $83.8 million, an increase from $44.1 million in 2024, primarily driven by higher selling, general and administrative expenses, and manufacturing and supply expenses, and decreases in revenue, partially offset by decreases in R&D expenses and increases in interest income.
Non-GAAP adjusted EBITDA loss (Q4 2025) $14.1 million, an increase from $11 million in Q4 2024, primarily due to higher selling, general and administrative expenses.
Non-GAAP adjusted EBITDA loss (Full Year 2025) $49.7 million, an increase from $23 million in 2024, primarily due to higher selling, general and administrative expenses.
Cash and cash equivalents (End of 2025) $121.2 million, providing a cash runway to support costs associated with the Anaphylm NDA resubmission, pre-commercial infrastructure, regulatory submissions, and clinical trials.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Anaphylm NDA resubmission: Aquestive is preparing to resubmit the NDA for Anaphylm in Q3 2026, following clear instructions from the FDA. The company has selected clinical research organizations for required studies and modified packaging for easier use.
Anaphylm launch preparation: Aquestive plans to launch Anaphylm with 75 sales representatives, a 50% increase from prior guidance, aiming for a cash-neutral position by 2027.
AdrenaVerse platform: Aquestive continues to develop its prodrug epinephrine platform, with an IND for AQST-108 opened in December 2025 and initial safety study completed.
Market expansion for Anaphylm: Aquestive plans to file regulatory submissions for Anaphylm in Europe and Canada by the end of 2026 and is engaging with the U.K. health authority.
Licensing strategy: The company is focusing on licensing Libervant in the U.S. and Anaphylm in Europe, with active discussions underway.
Revenue growth: Total revenues increased by 10% in Q4 2025 compared to Q4 2024, driven by manufacturing and supply revenue.
Cost management: R&D expenses decreased in 2025 due to lower clinical trial costs, while SG&A expenses increased due to legal fees and commercial spending for Anaphylm.
Litigation resolution: Aquestive settled a 9-year defamation lawsuit, marking the fourth lawsuit resolved in the past four years.
Investor confidence: RTW extended its revenue-sharing agreement and invested an additional $5 million, supporting Anaphylm's potential launch.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Challenges: The company faces significant risks and uncertainties related to the development, regulatory approval, and commercialization of its products, particularly Anaphylm. The FDA has requested additional studies, including a human factor study and PK study, which could delay approval timelines.
Financial Risks: Launching a prescription drug like Anaphylm requires considerable capital. The company has incurred significant losses, with a net loss of $83.8 million in 2025, and is dependent on external financing, such as the extended agreement with RTW, to support its operations and potential product launch.
Market Competition: The allergy market is dominated by auto-injectors and medical devices, with over 90% of prescriptions in this category. Convincing patients and physicians to switch to an oral film product like Anaphylm may be challenging.
Litigation Risks: The company has been involved in multiple lawsuits, including a 9-year-long defamation lawsuit recently settled. While some lawsuits have been resolved, ongoing or future litigation could pose financial and operational risks.
Operational Challenges: The company plans to double its medical affairs team and increase its sales force by 50% upon Anaphylm's approval. These expansions require careful execution to avoid operational inefficiencies and cost overruns.
Product Launch Risks: Launching Anaphylm in the U.S. is described as extremely difficult, requiring significant marketing efforts, payer negotiations, and a well-coordinated sales strategy. Delays or missteps in these areas could impact the product's success.
Revenue Dependence: The company’s revenue is heavily reliant on manufacturing and supply agreements for existing products like Suboxone and Ondif. Any disruptions in these agreements could adversely affect financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Anaphylm NDA Resubmission: Aquestive plans to resubmit the NDA for Anaphylm in Q3 2026, following discussions with the FDA and completion of required studies.
Anaphylm Launch Preparation: The company is preparing for a potential U.S. launch of Anaphylm, with plans to increase the sales team to 75 representatives, a 50% increase from prior guidance, aiming for a cash-neutral position by the end of 2027.
International Expansion: Aquestive aims to file regulatory submissions for Anaphylm in Europe and Canada by the end of 2026 and is engaging with the U.K. health authority (MHRA).
RTW Revenue Sharing Agreement: RTW has extended its revenue sharing agreement with Aquestive until June 30, 2027, and committed additional capital to support the potential launch of Anaphylm.
Market Trends: The allergy market is growing, with a 9% overall increase in 2025. The company sees strong potential for Anaphylm as the first oral epinephrine product, with over 90% of prescriptions currently using auto-injectors.
Libervant Licensing: Aquestive plans to focus on licensing Libervant in the U.S. and is in discussions with multiple interested parties. Licensing is also planned for Anaphylm in Europe.
AdrenaVerse Platform: Aquestive is advancing its AdrenaVerse platform, with an IND for AQST-108 opened in December 2025 and initial safety study dosing completed. Top-line clinical data is expected soon.
2026 Financial Guidance: Aquestive projects total revenue of $46 million to $50 million and a non-GAAP adjusted EBITDA loss of $30 million to $35 million for 2026. The company expects to end 2026 with approximately $70 million in cash, excluding additional proceeds from RTW or licensing transactions.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Has the Type A meeting with the FDA been scheduled?
A:The request for the Type A meeting has been submitted, but it has not been scheduled yet. The FDA guidelines suggest the meeting should occur within 30 days of the request, so it is expected to happen by the end of the month or early April.
Q:What are the main goals for the Type A meeting with the FDA?
A:The main goals are to ensure alignment with the FDA on how to execute the two studies requested in the CRL and to clarify any questions regarding the research.
Q:What modifications are being made to the proposed protocol mentioned in the CRL?
A:The modification is minor, and the company is seeking clarity from the FDA on how they are thinking about it. The company is prepared to proceed based on the FDA's response.
Q:Why was the RTW agreement extended to June 30, 2027, and have the terms changed?
A:The extension to June 30, 2027, was made for simplicity, but the company does not expect to need that much time. The terms of the agreement, including the $75 million, have not changed.
Q:Why is the company adding 50% more sales reps?
A:The decision was driven by the need for greater efficiency, better coverage, and the ability to penetrate deeper into the allergist and pediatrician markets. Smaller territories will allow reps to be more effective and reduce travel time.
Q:How was the trial design for the FDA meeting determined, and are modifications expected?
A:The trial design aligns with the FDA's requests, and the company is prepared to make modifications if necessary. The design includes optionality to meet the FDA's requirements.
Q:What is the company's approach to direct-to-consumer (DTC) advertising?
A:The company plans to focus on direct interactions with reps rather than DTC advertising, as the competitor's DTC efforts are already growing the market.
Q:What is the status of AQST-108 and its potential indications?
A:The company is focused on alopecia areata but is also exploring other indications based on ongoing trials and data. The development of AQST-108 is linked to the progress of Anaphylm.
Q:What is the timing for hiring additional sales reps?
A:The hiring process will begin before approval, with contingent offers made so that reps can start immediately upon approval. This approach will not delay the launch.
Q:What is the status of the citizen petition filed by a competitor?
A:The FDA denied the citizen petition, which the company views as a validation of their data package.
Q:What were the key takeaways from the AAAAI conference?
A:The allergist community is optimistic about the company's ability to get approval and is excited about the product. There is significant interest and curiosity about the new treatment option.
Q:How does the company view the requirements for the PK study?
A:The company is prepared to meet the FDA's requirements, including healthcare-administered Anaphylm, self-administered Anaphylm, and top-of-tongue administration. They are ready to adjust based on the FDA's feedback.
Q:What is the importance of diastolic blood pressure data presented at AAAAI?
A:The data showed no initial dip in diastolic blood pressure with Anaphylm, which may improve mean arterial pressure and support resuscitation during shock.
Q:What is the company's stance on tolerability concerns?
A:The company believes tolerability concerns are minimal and will better characterize their product's tolerability compared to alternatives in their resubmission.
Q:What is the timeline for Anaphylm's NDA resubmission and potential approval?
A:The company expects a 6-month review period but is hopeful for a faster approval based on the competitor's experience. They aim to launch within 8 weeks of approval.
Q:What is the timeline for international submissions for Anaphylm?
A:Submissions for Europe and Canada are planned for 2026, after the U.S. submission.
Q:What is the company's plan for Libervant?
A:The company has decided to prioritize Anaphylm over Libervant due to resource constraints. They are exploring partnerships and licensing opportunities for Libervant.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact question for the FDA regarding the protocol modification, stating they would share more in a few weeks. They also did not disclose the settlement terms with Neurelis, citing confidentiality. Additionally, they did not provide a detailed timeline for the next stage of clinical development for AQST-108, stating it is linked to Anaphylm's progress.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AAAAI addition
AQST dosing
Academy Allergy
AdrenaVerse prodrug
Affairs Chief
American Academy
Anaphylm FDA
Anaphylm human
Anaphylm path
Anaphylm term
Aquestive addition
Aquestive evolution
Aquestive fact
Aquestive path
Aquestive website
Chief Commercial
Commercial Officer
Ernie
Europe
PK study
President
QA session
RTW
addition Dr
auto injector
capital
future
injector market
investor
lawsuit
leader
optimism
organization
packaging
party
rep
resubmission
study FDA
AQST Transcript
Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call presents a mixed outlook. The FDA approval and launch of Anaphylm, along with international expansion plans, suggest potential growth. However, financial guidance shows a significant EBITDA loss, and there are uncertainties regarding FDA meetings and protocol modifications. The Q&A reveals positive sentiment from the allergist community and readiness for regulatory requirements, but management's vague responses on certain issues raise concerns. Overall, the combination of positive development plans and financial challenges results in a neutral sentiment.
Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call summary presents a mixed outlook. Positive aspects include the FDA approval track for Anaphylm, international expansion plans, and new patents. However, financial guidance indicates a significant EBITDA loss, and management was vague on pricing and partnerships. The Q&A revealed cautious optimism but also highlighted uncertainties, such as pricing and international strategies. Considering these factors, the overall sentiment is neutral, anticipating limited stock price movement.
Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call reveals a decline in revenue, increased expenses, and a substantial net loss, which are negative indicators. The Q&A session highlights uncertainties regarding FDA approval and payer engagement, further dampening sentiment. Despite robust clinical data, the lack of clear guidance on coverage and the need for additional funding for a full-scale launch contribute to a negative outlook. The absence of a new partnership announcement or positive financial metrics, coupled with the increased net loss and EBITDA loss, supports a negative stock price reaction.
Earnings call transcript: Aquestive’s Q1 2025 earnings miss, stock drops 7%
Unknown5-13
The earnings call highlights several concerning elements: a significant revenue decline, increased losses, and vague management responses in the Q&A. Despite preparations for ANNAFILM's launch, the lack of clear guidance on AdCom topics and potential impacts of new FDA personnel raises uncertainty. Additionally, the competitive pressure from existing products like EpiPen and NEFI, combined with potential operational risks, further contribute to a negative sentiment. The market may react negatively due to these uncertainties, leading to a predicted stock price movement of -2% to -8% over the next two weeks.
AQST Slides
AQST Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
